Jeff Binder Named President of Immucor
July 28, 2016 at 4:25 p.m.
By Staff Report-
Binder succeeded CEO William A. Hawkins III, who now takes the role of lead director on the Immucor Board of Directors.
Binder, a 22-year veteran of the healthcare industry, has experience in helping companies realize growth opportunities, the announcement states. He was president and CEO of orthopedic maker Biomet from Feb. 26, 2007, to Wednesday. He received $45 million in the sale, mainly in stock awards, according to the Associated Press.
“Jeff joins Immucor with a wealth of experience and a proven track record of success in the healthcare industry,” Todd Sisitsky, managing partner of TPG Capital North America, said in the announcement. “Having worked with Jeff over the past eight years, we believe he is one of the most talented executives in healthcare and is uniquely qualified to lead Immucor into its next chapter of growth. We are pleased that Jeff will also serve as a senior advisor to TPG Capital.”
Binder is quoted as saying, “Immucor is an innovative market-leader that is revolutionizing transfusion and transplant medicine, and I look forward to the opportunity to work with the excellent management team and employees to further capitalize on market opportunities. I’ve thoroughly enjoyed working with the TPG team during my tenure at Biomet, and know that together we can form another successful partnership at Immucor.”
Before Biomet, Binder served as senior vice president of Diagnostic Operations of Abbott Laboratories, president of Abbott Spine and president and CEO of Spinal Concepts. Prior to Spinal Concepts, he was president of DePuy Orthopedics joint reconstruction and trauma business following its integration with Johnson & Johnson. He also held various senior positions at Howmedica Orthopedics and with the Boston Consulting Group.[[In-content Ad]]
Binder succeeded CEO William A. Hawkins III, who now takes the role of lead director on the Immucor Board of Directors.
Binder, a 22-year veteran of the healthcare industry, has experience in helping companies realize growth opportunities, the announcement states. He was president and CEO of orthopedic maker Biomet from Feb. 26, 2007, to Wednesday. He received $45 million in the sale, mainly in stock awards, according to the Associated Press.
“Jeff joins Immucor with a wealth of experience and a proven track record of success in the healthcare industry,” Todd Sisitsky, managing partner of TPG Capital North America, said in the announcement. “Having worked with Jeff over the past eight years, we believe he is one of the most talented executives in healthcare and is uniquely qualified to lead Immucor into its next chapter of growth. We are pleased that Jeff will also serve as a senior advisor to TPG Capital.”
Binder is quoted as saying, “Immucor is an innovative market-leader that is revolutionizing transfusion and transplant medicine, and I look forward to the opportunity to work with the excellent management team and employees to further capitalize on market opportunities. I’ve thoroughly enjoyed working with the TPG team during my tenure at Biomet, and know that together we can form another successful partnership at Immucor.”
Before Biomet, Binder served as senior vice president of Diagnostic Operations of Abbott Laboratories, president of Abbott Spine and president and CEO of Spinal Concepts. Prior to Spinal Concepts, he was president of DePuy Orthopedics joint reconstruction and trauma business following its integration with Johnson & Johnson. He also held various senior positions at Howmedica Orthopedics and with the Boston Consulting Group.[[In-content Ad]]
Have a news tip? Email [email protected] or Call/Text 360-922-3092